Interstitial lung disease in mixed connective tissue disease

Marshell Tendean, Sazkia Aziza Nuriawan, Pringgodigdo Nugroho

Research output: Contribution to journalArticlepeer-review


Interstitial lung diseases (ILD) are known as a debilitating pulmonary complications that may be occured in almost all systemic connective tissue diseases (CTD), including mixed connective tissue disease (MCTD). ILD is usually found in more than half of MCTD patients after 2-4 years after the diagnosis made. A-47-years-old female initially diagnosed as systemic lupus erythematosus (SLE) developed a severe progressive dyspnea. She has recently diagnosed as MCTD with ILD after 9 months of initial symptoms. She was giving with Cyclophosphamide 500 mg IV pulse dose. However, after 1 months she developed severe pneumonia and pronounced demise due to intractable septic shock. The debilitating course of ILD is commonly seen in most systemic CTD. Therefore, it is important to perform initial screening and prevention. Systemic corticosteroid with or without immunosupressor agent(s) are indicated in ILD-MCTD. Patients with progressive diseases will have poor prognosis.
Original languageEnglish
Pages (from-to)29-33
JournalIndonesian Journal of Rheumatology
Issue number1
Publication statusPublished - 1 Jan 2017


  • ILD, MCTD, Corticosteroid


Dive into the research topics of 'Interstitial lung disease in mixed connective tissue disease'. Together they form a unique fingerprint.

Cite this